From GlobeNewswire: 2025-05-13 20:01:00

HCW Biologics Inc. announced the pricing of its follow-on offering of 671,140 units at $7.45 per unit, totaling approximately $5.0 million in gross proceeds. The offering includes one share of common stock and two warrants per unit, with each warrant exercisable at $7.45 per share. The Company plans to use the net proceeds for preclinical and clinical development, business development, and general corporate purposes. Additionally, HCW Biologics reduced the exercise price of certain existing warrants from $41.20 to $7.45 per share. The offering is expected to close on May 15, 2025, pending customary closing conditions (Source: Globe Newswire).

HCW Biologics Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies to treat age-related and senescence-associated diseases. Their lead product candidate, HCW9302, utilizes the Company’s proprietary TOBI platform to target chronic inflammation and potentially improve patient quality of life. The Company has developed the TRBC platform to create immunotherapeutics that activate immune responses and target specific cells, with over 50 molecules in development. HCW Biologics aims to revolutionize disease treatment through innovative drug discovery technologies and strategic licensing programs (Source: Globe Newswire).



Read more at GlobeNewswire: HCW Biologics Announces Pricing of $5.0 Million Follow-On